What Causes DCIS? Genes, Hormones, and Lifestyle

DCIS, or ductal carcinoma in situ, arises from a combination of inherited genetic susceptibility, cumulative hormone exposure, and certain modifiable factors like body weight. It is a growth of abnormal cells inside the milk ducts of the breast that has not broken through the surrounding membrane into neighboring tissue.¹ Because the cells stay contained, DCIS is classified as non-invasive, but the factors that set it in motion overlap heavily with those behind invasive breast cancer, and some of them are genuinely surprising in how weak or strong their effects turn out to be.²

Inherited Gene Mutations That Raise DCIS Risk

The gene most people associate with breast cancer is BRCA, and both BRCA1 and BRCA2 mutations do play a role in DCIS. Among women carrying a BRCA mutation, roughly a fifth to a third of breast tumors include a DCIS component.³ BRCA1 carriers tend to develop higher-grade DCIS, while BRCA2 mutations carry a particularly high risk of DCIS itself, with one large study finding that BRCA2 variants were associated with more than a fourfold increase in DCIS risk.^{4 5}

BRCA is not the whole genetic story, though. A study of both population-based and clinical-testing cohorts identified four cancer-predisposition genes linked to elevated DCIS risk: BRCA1, CHEK2, PALB2, and ATM. BRCA2 showed the strongest association, while ATM, CHEK2, and PALB2 each carried a moderate increase in risk.⁵ For CHEK2 specifically, a study of Polish women found that truncating mutations roughly tripled the odds of DCIS, and the risk climbed even higher when those mutations combined with a family history of breast cancer.⁶

These are all single-gene mutations with relatively clear effects. But most women who develop DCIS do not carry any of them. That is where the broader genetic landscape comes in.

Polygenic Risk and the Cumulative Effect of Common Variants

Rather than one dramatic mutation, many women carry a collection of small genetic variations, each individually minor, that together push breast cancer risk up or down. Researchers capture this using a polygenic risk score, which tallies the combined effect of hundreds of common gene variants. A score built from 313 known breast-cancer-associated variants was recently tested in women who had already been diagnosed with DCIS. Women in the top quarter of polygenic risk had roughly double the chance of developing cancer in the opposite breast compared with women in the bottom quarter, even after accounting for tumor grade, treatment, and family history.⁷

The practical implication is that genetic risk for DCIS is not limited to the rare, high-profile mutations. A woman without any known BRCA or CHEK2 variant can still carry a genetically elevated risk that shapes both her likelihood of developing DCIS and her outcomes afterward. Polygenic risk scores are not yet standard in clinical decision-making for DCIS, but the research is moving in that direction.

Epigenetic Alterations in DCIS

Genes can also be switched on or off without the DNA sequence itself changing, through chemical modifications called epigenetic marks. One of the most studied is DNA methylation, where small molecules attach to gene promoters and silence them. In DCIS, the methylation landscape is drastically different from normal breast tissue, involving changes in thousands of genes.⁸ The pattern of which genes are methylated in DCIS closely resembles the pattern seen in invasive ductal carcinoma, suggesting these changes happen early in the process rather than only after a tumor becomes aggressive.⁹

Researchers are interested in methylation markers partly because they could help distinguish which cases of DCIS are likely to progress and which will stay harmless. Traditional measures like tumor grade are imperfect predictors, and methylation-based markers may eventually prove more accurate.¹⁰

How Hormones Drive DCIS

Estrogen is the dominant hormonal influence on both DCIS and invasive breast cancer. Estrogen, sometimes amplified by progesterone, promotes cell division in breast tissue. More cell divisions mean more opportunities for mutations to arise and take hold.¹¹ Any factor that increases a woman’s total lifetime estrogen exposure tends to raise DCIS risk: starting periods early, going through menopause late, or never having children. Recent epidemiological evidence suggests that early menarche may carry a stronger effect than late menopause, though both contribute.¹²

In a large cohort of postmenopausal women, late menopause (at 55 or older, compared with 45 to 54) was associated with about a 40 percent increase in DCIS risk. Having five or more children showed a possible protective effect, while having a first child after age 30 trended toward higher risk, though neither finding reached full statistical certainty.¹³

Hormone Replacement Therapy

Hormone replacement therapy (HRT) after menopause is one of the clearest modifiable hormonal risk factors. In a nationwide population-based cohort, the increase in breast cancer incidence, including DCIS, climbed proportionally with the duration of HRT use.¹⁴ This fits neatly with the estrogen-exposure model: HRT essentially extends the hormonal environment of premenopause into years when the body would otherwise have lower estrogen levels.

The risk from HRT is real but also context-dependent. Women who use HRT for a short period to manage severe menopausal symptoms face a smaller cumulative exposure than those who use it for a decade or more. The decision involves trade-offs that go beyond breast risk alone, which is why it remains a conversation between patient and physician rather than a blanket recommendation.

Estrogen Receptor Status and What It Tells Us

About three-quarters of DCIS cases test positive for estrogen receptors, meaning the abnormal cells have molecular antennae that respond to estrogen.¹⁵ Nearly all low-grade and intermediate-grade DCIS is estrogen-receptor positive, while high-grade DCIS is a more mixed picture, with roughly half to slightly more than half testing positive.¹⁶ When DCIS becomes microinvasive, the rate of estrogen-receptor positivity drops considerably, suggesting that the cells gaining the ability to spread are less dependent on hormonal signals.¹⁷

This matters practically because estrogen-receptor positive DCIS is the type most likely to respond to anti-estrogen treatments like tamoxifen. It also suggests that the hormonal causes discussed above are especially relevant to the most common form of DCIS, while the rarer estrogen-receptor negative cases are driven more by other molecular pathways.

The HER2 Connection

HER2, a protein that encourages cell growth, is overexpressed in about one in five DCIS cases. In a large single-institution study, HER2-positive DCIS was strongly associated with features of aggressiveness, including higher grade and more frequent local recurrence.¹⁸ Data from a randomized trial found that HER2-positive DCIS carried more than double the risk of same-breast recurrence compared with HER2-negative cases, driven mainly by a threefold higher chance of recurring as in situ disease.¹⁹

High-grade DCIS cases that combine low progesterone receptor levels with high cell-proliferation markers are frequently HER2-enriched, forming a distinct molecular subtype that behaves differently from the hormone-driven majority.²⁰ HER2 overexpression is not exactly a “cause” of DCIS the way a BRCA mutation or estrogen exposure is. It is more an internal molecular event that shapes how a particular case behaves and whether it is likely to recur.

Breast Density as a Physical Risk Factor

Dense breast tissue, where a mammogram shows more fibrous and glandular tissue relative to fat, is a well-established risk factor. Women with the highest breast density (50 percent or more on mammography) had roughly three times the odds of DCIS compared with women with the least dense breasts in a multiethnic cohort study.²¹ The risk gradient was present in both premenopausal and postmenopausal women, though the magnitude differed. Among premenopausal women, extremely dense breasts were associated with about a 2.4-fold increase in DCIS risk relative to scattered density, while postmenopausal women with heterogeneously dense breasts had about a 1.4-fold increase.²²

Dense tissue is thought to provide a richer environment for abnormal cell growth, but it also complicates detection: calcifications and small abnormalities are harder to spot on a mammogram when the surrounding tissue is already bright white. This creates a double problem of both higher biological risk and a greater chance that early changes go unnoticed.

Body Weight and Obesity

Among postmenopausal women not taking HRT, having a body mass index of 30 or above was linked to higher DCIS risk in the large UK Biobank cohort.²³ The biological connection makes sense: fat tissue converts precursor hormones into estrogen, and in postmenopausal women whose ovaries have stopped producing estrogen, this becomes the primary source. Higher body fat means higher circulating estrogen.²⁴ The link is strongest in postmenopausal women specifically because, before menopause, ovarian production dominates and extra estrogen from fat tissue has less relative impact.

Alcohol, Exercise, and Smoking

Alcohol is a known risk factor for invasive breast cancer, partly because it raises estrogen levels. But for DCIS specifically, the evidence is weaker than you might expect. A large study of postmenopausal women found no association between alcohol intake and DCIS risk at any level of consumption, including heavy drinking of 14 or more servings per week.²⁵ This does not mean alcohol is safe for breast health broadly, but its specific connection to DCIS, as opposed to invasive cancer, is unclear.

Physical activity tells a somewhat mixed story as well. One case-control study found that women who exercised had roughly a 35 percent lower risk of breast carcinoma in situ compared with inactive women, especially among those without a family history.²⁶ However, a large cohort study of postmenopausal women found no meaningful association between recreational physical activity and DCIS risk, even at the highest levels of exercise.²⁷ Exercise almost certainly helps with breast cancer risk in general, likely by keeping body weight down and improving hormonal balance, but a direct protective effect against DCIS has not been consistently demonstrated.

Smoking is another area where DCIS defies expectations. A large cohort study of postmenopausal women found little support for any association between smoking and DCIS risk, regardless of smoking intensity, duration, or pack-years.²⁸ One earlier study even found a slight inverse association among current smokers who were regularly screened by mammography, though the researchers suspected this reflected detection differences rather than a genuine protective effect of smoking.²⁹ Smoking causes dozens of cancers and countless other diseases, so this finding says more about the specifics of DCIS biology than about smoking being harmless.

What About Dietary Fat?

Reducing dietary fat has long been suggested as a way to lower breast cancer risk, but the Women’s Health Initiative, one of the largest controlled dietary trials ever conducted, found no evidence that a low-fat dietary intervention changed DCIS risk. The null result held in the overall group and in subgroups defined by other risk factors.³⁰ This does not rule out a role for diet entirely, but simple fat reduction, at least as tested in postmenopausal women, does not appear to move the needle for DCIS.

How DCIS Progresses and Why Most Cases Do Not

What keeps DCIS non-invasive is the basement membrane, a thin but structurally important barrier surrounding the milk duct. As long as the abnormal cells stay on the inside of this membrane, they cannot reach blood vessels or lymph nodes and therefore cannot spread to other parts of the body.³¹ The transition from in situ to invasive disease is not driven solely by changes inside the tumor cells. The microenvironment surrounding them, including immune cells, connective tissue cells called fibroblasts, and the structural matrix itself, plays a large role in whether the membrane holds or gives way.³²

Different molecular subtypes of DCIS appear to follow distinct paths. HER2-enriched and high-grade DCIS interact with the surrounding tissue differently than low-grade, hormone-driven DCIS. Researchers have identified specific genes whose activity differs between DCIS that stays put and DCIS that advances, and knocking down or boosting those genes in lab experiments can suppress or encourage the invasive behavior of breast cancer cells.³³ The challenge clinically is that we still cannot reliably predict which individual case of DCIS will progress. Most will not, but identifying the exceptions remains an active area of research.

The Screening Factor

One cause of DCIS that gets less attention is the very thing that detects it. Before widespread mammography screening began, DCIS was rarely diagnosed. Over the three decades following the introduction of screening in the United States, the number of early-stage breast cancers detected each year roughly doubled, with DCIS accounting for a substantial share of that increase.³⁴ Screening does not cause DCIS in a biological sense, but it finds cases that, in an earlier era, would have gone undetected and may never have caused symptoms. This has fueled a long-running debate about overdiagnosis: the concern that some women are treated for a condition that would never have threatened their health.

Women who received chest radiation for other conditions, such as treatment for lymphoma earlier in life, face an elevated risk of breast abnormalities including DCIS. MRI screening in this population has detected breast cancers, including DCIS, that mammography alone missed.³⁵ Prior chest radiation is a distinct environmental cause worth knowing about, especially because it creates risk decades after the original exposure and warrants earlier and more intensive surveillance than standard screening guidelines suggest.